 JUPITER, FL ACCESSWIRE July 15, 2020 Dyadic International, Inc. Dyadic, we, us, our, or the Company DYAI, a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a new, fully-funded collaboration with another top five global pharmaceutical company. Additionally, we have been able to demonstrate the broad applications of our C1 technology, which in turn has resulted in many new wide-ranging opportunities. 